Women are more likely than men not to take their diabetes medication as prescribed in an effort to control prescription drug costs, as are adults under age 65, according to a report published this month by the Centers for Disease Control and Prevention (CDC).
Women are more likely than men not to take their diabetes medication as prescribed in an effort to control prescription drug costs, as are adults under age 65, according to a report published this month by the Centers for Disease Control and Prevention (CDC).
The August data brief used data from the 2017-2018 National Health Interview Survey (NHIS), looking who was more likely to ration diabetes medications as a cost-savings measure during the past 12 months.
Despite a recent shift to lower-cost options as the first line of diabetes therapy, the burden of high prescription drug costs remains a public health concern, the CDC noted. The price of insulin has been the topic of numerous hearing on Capitol Hill, and some companies have responded by introducing authorized generics or by capping prices as the wait for cheaper biosimilar insulin continues. Rationing of insulin and other supplies needed to manage diabetes is known to be a worldwide problem.
Last year, diabetes medications ranked sixth out of the top 20 therapeutic classes of dispensed prescriptions, accounting for 214 million prescriptions. In 2017, the annual per capita expense for outpatient diabetes medication was almost $5000, the CDC said.
Among adults with diagnosed diabetes, women (14.9%) were more likely than men (11.6%) not to take their medication as prescribed, although they were as likely to ask their doctor for a lower-priced medication (25.5% vs 23.4%).
The survey also found that uninsured adults aged 18 to 64 years were more likely than those with private insurance or Medicaid to not take their medication as prescribed and to ask their doctor for a lower-cost drug. Almost 36% of the uninsured did not take medication as prescribed, compared with 14% of those with private health insurance and nearly 18% of those with Medicaid coverage. Likewise, 42.6% of uninsured adults were more likely to seek out cheaper prescriptions, compared with patients who had private coverage (25.7%) or Medicaid coverage (18.8%).
Younger adults were more likely than those aged 65 and over to not take their medication as prescribed (17.9% and 7.2%, respectively) and to ask their doctor for a lower-cost drug (26.3% and 21.9%, respectively).
Among adults aged 65 and over, the percentage who did not take their diabetes medication as prescribed did not vary significantly by coverage type (private coverage, Medicare and Medicaid, Medicare Advantage, traditional fee-for-service Medicare only, other coverage, or no insurance), ranging from 6.2% for those with private insurance to 9.2% for those with traditional Medicare.
Within this group, the percentage of patients who asked their doctor for a lower-cost diabetes medication was lowest among those with Medicare and Medicaid coverage (13.0% each) compared with private (26.1%), Medicare Advantage (25.8%), or Medicare only (22.7%) coverage.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.